vs
Side-by-side financial comparison of Baxter International (BAX) and C.H. Robinson (CHRW). Click either name above to swap in a different company.
C.H. Robinson is the larger business by last-quarter revenue ($3.9B vs $3.0B, roughly 1.3× Baxter International). C.H. Robinson runs the higher net margin — 3.5% vs -37.9%, a 41.4% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs -6.5%). Over the past eight quarters, C.H. Robinson's revenue compounded faster (-5.8% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
C.H. Robinson Worldwide, Inc. is an American transportation company that includes third-party logistics (3PL). The company offers freight transportation, transportation management, brokerage and warehousing. It offers truckload, less than truckload, air freight, intermodal, and ocean transportation.
BAX vs CHRW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $3.9B |
| Net Profit | $-1.1B | $136.3M |
| Gross Margin | 19.4% | — |
| Operating Margin | -24.5% | 4.6% |
| Net Margin | -37.9% | 3.5% |
| Revenue YoY | 458.0% | -6.5% |
| Net Profit YoY | -120.3% | -8.7% |
| EPS (diluted) | $-2.21 | $1.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $3.9B | ||
| Q3 25 | $2.8B | $4.1B | ||
| Q2 25 | $2.8B | $4.1B | ||
| Q1 25 | $2.6B | $4.0B | ||
| Q4 24 | $533.0M | $4.2B | ||
| Q3 24 | $2.7B | $4.6B | ||
| Q2 24 | $3.8B | $4.5B | ||
| Q1 24 | $3.6B | $4.4B |
| Q4 25 | $-1.1B | $136.3M | ||
| Q3 25 | $-46.0M | $163.0M | ||
| Q2 25 | $91.0M | $152.5M | ||
| Q1 25 | $126.0M | $135.3M | ||
| Q4 24 | $-512.0M | $149.3M | ||
| Q3 24 | $140.0M | $97.2M | ||
| Q2 24 | $-314.0M | $126.3M | ||
| Q1 24 | $37.0M | $92.9M |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — | ||
| Q1 24 | 38.6% | — |
| Q4 25 | -24.5% | 4.6% | ||
| Q3 25 | 6.1% | 5.3% | ||
| Q2 25 | 6.8% | 5.2% | ||
| Q1 25 | 2.2% | 4.4% | ||
| Q4 24 | -25.5% | 4.4% | ||
| Q3 24 | 5.7% | 3.9% | ||
| Q2 24 | -5.0% | 4.0% | ||
| Q1 24 | 5.2% | 2.9% |
| Q4 25 | -37.9% | 3.5% | ||
| Q3 25 | -1.6% | 3.9% | ||
| Q2 25 | 3.2% | 3.7% | ||
| Q1 25 | 4.8% | 3.3% | ||
| Q4 24 | -96.1% | 3.6% | ||
| Q3 24 | 5.2% | 2.1% | ||
| Q2 24 | -8.2% | 2.8% | ||
| Q1 24 | 1.0% | 2.1% |
| Q4 25 | $-2.21 | $1.12 | ||
| Q3 25 | $-0.09 | $1.34 | ||
| Q2 25 | $0.18 | $1.26 | ||
| Q1 25 | $0.25 | $1.11 | ||
| Q4 24 | $-0.99 | $1.23 | ||
| Q3 24 | $0.27 | $0.80 | ||
| Q2 24 | $-0.62 | $1.05 | ||
| Q1 24 | $0.07 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $160.9M |
| Total DebtLower is stronger | $9.5B | $1.1B |
| Stockholders' EquityBook value | $6.1B | $1.8B |
| Total Assets | $20.1B | $5.1B |
| Debt / EquityLower = less leverage | 1.55× | 0.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $160.9M | ||
| Q3 25 | $1.7B | $136.8M | ||
| Q2 25 | $1.7B | $156.0M | ||
| Q1 25 | $2.3B | $129.9M | ||
| Q4 24 | $1.8B | $145.8M | ||
| Q3 24 | $1.4B | $131.7M | ||
| Q2 24 | $2.1B | $113.2M | ||
| Q1 24 | $3.0B | $121.8M |
| Q4 25 | $9.5B | $1.1B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $10.4B | $1.4B | ||
| Q3 24 | $10.4B | $1.6B | ||
| Q2 24 | $10.4B | $1.6B | ||
| Q1 24 | $11.1B | $1.7B |
| Q4 25 | $6.1B | $1.8B | ||
| Q3 25 | $7.2B | $1.9B | ||
| Q2 25 | $7.3B | $1.8B | ||
| Q1 25 | $7.1B | $1.7B | ||
| Q4 24 | $7.0B | $1.7B | ||
| Q3 24 | $7.9B | $1.6B | ||
| Q2 24 | $7.6B | $1.5B | ||
| Q1 24 | $8.2B | $1.4B |
| Q4 25 | $20.1B | $5.1B | ||
| Q3 25 | $21.1B | $5.2B | ||
| Q2 25 | $21.0B | $5.3B | ||
| Q1 25 | $21.3B | $5.2B | ||
| Q4 24 | $25.8B | $5.3B | ||
| Q3 24 | $26.7B | $5.6B | ||
| Q2 24 | $26.3B | $5.5B | ||
| Q1 24 | $27.8B | $5.5B |
| Q4 25 | 1.55× | 0.59× | ||
| Q3 25 | — | 0.64× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | 1.49× | 0.80× | ||
| Q3 24 | 1.33× | 0.95× | ||
| Q2 24 | 1.37× | 1.07× | ||
| Q1 24 | 1.36× | 1.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $305.4M |
| Free Cash FlowOCF − Capex | — | $302.4M |
| FCF MarginFCF / Revenue | — | 7.7% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 2.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $894.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $305.4M | ||
| Q3 25 | $237.0M | $275.4M | ||
| Q2 25 | $217.0M | $227.1M | ||
| Q1 25 | $-193.0M | $106.5M | ||
| Q4 24 | $488.0M | $267.9M | ||
| Q3 24 | $253.0M | $108.1M | ||
| Q2 24 | $115.0M | $166.4M | ||
| Q1 24 | $163.0M | $-33.3M |
| Q4 25 | — | $302.4M | ||
| Q3 25 | — | $269.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | — | $103.2M | ||
| Q4 24 | — | $265.3M | ||
| Q3 24 | — | $103.3M | ||
| Q2 24 | — | $159.8M | ||
| Q1 24 | — | $-41.9M |
| Q4 25 | — | 7.7% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | -1.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 2.24× | ||
| Q3 25 | — | 1.69× | ||
| Q2 25 | 2.38× | 1.49× | ||
| Q1 25 | -1.53× | 0.79× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | 1.81× | 1.11× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | 4.41× | -0.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
CHRW
| North American Service Transportation NAST | $2.8B | 72% |
| Global Forwarding | $731.0M | 19% |
| Sourcing | $340.9M | 9% |
